Amisulpride IV
BARHEMSYS
“Am I soul bride?”
QT prolongation
prolactin elevation
What it isThe only US-approved amisulpride: an IV antiemetic (BARHEMSYS, 2020), not an antipsychotic dose — 5 mg at induction prevents PONV, 10 mg after surgery treats it, infused over 1-2 minutes.
Why this oneA D2/D3 antagonist acting at the chemoreceptor trigger zone and area postrema; little sedation at these doses.
What limits itQT prolongation is dose- and concentration-dependent: avoid in congenital long QT and with droperidol; ECG monitoring with other QT-prolonging drugs (ondansetron). Half-life about 4-5 h, mostly renal.
FDA-approved for
- postoperative nausea/vomiting, prevention (5 mg) and treatment (10 mg) (2020)
NO BOXED WARNINGS
Principal riskDose- and concentration-dependent QT prolongation; avoid with droperidol and in congenital long QT
Classes and tags
Clinical profile
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilitySedation, QT prolongation, extrapyramidal symptoms or anticholinergic toxicity vary by receptor target.
Open Amisulpride IV in the interactive console ↗
Memory aids: interaction avatars
